SCHEMBL19084488

SCHEMBL19084488

Cc1c(F)ccc2c1cnn2C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.37
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36
PIP4K2A P48426 1/20 0.35
MAOA P21397 1/20 0.35
DAO P14920 1/20 0.34
F2RL1 P55085 1/20 0.34
TP53 P04637 1/20 0.32
APP P05067 1/20 0.32
TRPA1 O75762 1/20 0.32
TRPV1 Q8NER1 2/20 0.32
CACNA1H O95180 1/20 0.32
DRD4 P21917 1/20 0.32
TMEM97 Q5BJF2 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
KDR P35968 1/20 0.32
CCR4 P51679 1/20 0.31
HDAC4 P56524 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10310477 0.80 TP53 (0.39) BRD4CREBBPPIP4K2ATP53KDR
SCHEMBL27228291 0.79 PI4KA (0.37) MAOBPIP4K2AMAOAF2RL1TP53
SCHEMBL29766049 0.79 MAOB (0.36) MAOBPIP4K2AMAOAF2RL1TP53
SCHEMBL23115842 0.79 MAOB (0.36) MAOBPIP4K2AMAOAF2RL1TP53
SCHEMBL15518859 0.77 BRD4 (0.36) BRD4CREBBPTP53KDRCCR4
SCHEMBL13676392 0.77 PIP4K2A (0.38) MAOBCREBBPPIP4K2ATP53APP
SCHEMBL29769114 0.77 PIP4K2A (0.38) MAOBCREBBPPIP4K2ATP53APP
SCHEMBL19539232 0.74 CYP11B1 (0.44) TP53TRPV1KDRCCR4
SCHEMBL31171080 0.74 CYP11B1 (0.44) TP53TRPV1KDRCCR4
SCHEMBL19531654 0.74 BRD4 (0.34) BRD4CREBBPF2RL1TP53KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9988357-B2 Methods for preparation of quinazoline derivatives ARAXES PHARMA LLC (US) 2018-06-05 US disclosed
US-20170190672-A1 METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES ARAXES PHARMA LLC 2017-07-06 US disclosed
US-20150291625-A1 Heteroaromatic Compounds and their Use as Dopamine D1 Ligands PFIZER (US) 2015-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190672-A1 METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES TTBK2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TTBK1 MAOB 24/4885BRD4 825/4885CREBBP 3029/4885
US-20150291625-A1 Heteroaromatic Compounds and their Use as Dopamine D1 Ligands ARRB1, ADRA1D, ADRB1 MAOB 480/4885BRD4 1382/4885CREBBP 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.